CoChat
Sign Up
Cited by 254Parkinson's Disease Mechanisms and TreatmentsPharmaceutical Practices and Patient OutcomesDementia and Cognitive Impairment Research

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Use of drugs with anticholinergic effect and impact on cognition in Parkinson's disease: a cohort study

Ehrt, U., Broich, K., Larsen, J. P., Ballard, C., Aarsland, D.·2010·Journal of Neurology, Neurosurgery & Psychiatry
DOI 10.1136/jnnp.2009.186239
Open this paper in CoChat — free account

Abstract

Background Cognitive decline is common in Parkinson's disease (PD). Although some of the aetiological factors are known, it is not yet known whether drugs with anticholinergic activity (AA) contribute to this cognitive decline. Such knowledge would provide opportunities to prevent acceleration of cognitive decline in PD. Objective To study whether the use of agents with anticholinergic properties is an independent risk factor for cognitive decline in patients with PD. Methods A community-based cohort of patients with PD (n=235) were included and assessed at baseline. They were reassessed 4 and 8 years later. Cognition was assessed using the Mini-Mental State Examination (MMSE). A detailed assessment of the AA of all drugs prescribed was made, and AA was classified according to a standardised scale. Relationships between cognitive decline and AA load and duration of treatment were assessed using bivariate and multivariate statistical analyses. Results More than 40% used drugs with AA at baseline. During the 8-year follow-up, the cognitive decline was higher in those who had been taking AA drugs (median decline on MMSE 6.5 points) compared with those who had not taken such drugs (median decline 1 point; p=0.025). In linear regression analyses adjusting for age, baseline cognition and depression, significant associations with decline on MMSE were found for total AA load (standardised beta=0.229, p=0.04) as well as the duration of using AA drugs (standardised beta 0.231, p=0.032)…

Overview

Integrity signals

Registry

Crossref · 10.1136/jnnp.2009.186239

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Anticholinergic antiparkinson drugs have previously been associated with greater cognitive decline.

    “Patients with Parkinson’s disease have an elevated risk of dementia;44 anticholinergic antiparkinson drugs have previously been associated with greater cognitive decline.45”

    From Anticholinergic drugs and risk of dementia: case-control study (2018) · cites this paper as [45]

Citations

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Metadata

Authors
Ehrt, U., Broich, K., Larsen, J. P., Ballard, C., & Aarsland, D.
Affiliations
  • Stavanger University Hospital (NO)
  • Federal Institute for Drugs and Medical Devices (DE)
  • King's College London (GB)
Corresponding author
Ehrt, U.
ORCID
Venue
Journal of Neurology, Neurosurgery & Psychiatry
Publisher
BMJ
Published
2009-09-21
Volume
81
Issue
2
Pages
160-165
ISSN
0022-3050 (ISSN-L)
DOI
10.1136/jnnp.2009.186239
OpenAlex
W2150448794
Cited by
254
References
11
Citations by year
2026: 10 · 2025: 9 · 2024: 22 · 2023: 21 · 2022: 19 · 2021: 27 · 2020: 21 · 2019: 28 · 2018: 16 · 2017: 11 · 2016: 13 · 2015: 12 · 2014: 7 · 2013: 9 · 2012: 10
FWCI
6.03
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Neurology Neurosurgery & Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
  • Research Portal (King's College London) (submittedVersion)
  • HighWire Press Open Archive (submittedVersion)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
Parkinson's disease, anticholinergic agents, cognitive decline, anticholinergic burden, duration of drug use, Mini-Mental State Examination, adverse drug reactions, risk factors for cognitive decline
MeSH terms
Aged, Antidepressive Agents, Brain, Cognition Disorders, Major Depressive Disorder, Female, Follow-Up Studies, Humans, Male, Neuropsychological Tests, Parkinson Disease, Severity of Illness Index, Cohort Studies, Prevalence, Cholinergic Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review